Good Neighbor’s Diabetes Shoppe program wins honors for patient education newsletters
VALLEY FORGE, Pa. A series of health-oriented newsletters from Good Neighbor Pharmacy’s Diabetes Shoppe program has garnered honors for its effectiveness at helping people living with diabetes manage their disease.
GNP is the retail service division and branding program operated by AmerisourceBergen for independent pharmacies. The Living Without Limits newsletters published by Diabetes Shoppe – a program offered to GNP members specializing in the care of patients with diabetes – were recently awarded four awards for patient education by the National Health Information Awards Program. Living Without Limits won in several categories. Among them: a Gold Series Award for the past year’s issues of Living Without Limits for Kids, a Silver Series Award for the past year’s issues of Living Without Limits, and Bronze awards on single issues for both Living Without Limits and Living Without Limits for Kids.
The awards program is organized by the Health Information Resource Center, a national clearinghouse for consumer health information programs and materials. Diabetes Shoppe was competing with more than 1,000 entries submitted by leading organizations in the consumer health field, according to GNP.
The Living Without Limits newsletters are distributed to GNP locations across the United States that offer diabetes counseling and specialized services through the Diabetes Shoppe program. The newsletters contain health information, recipes, and information specific to patients with diabetes.
GSK: Rheumatoid arthritis treatment meets trial goals
LONDON A late-stage clinical trial of a biotech drug for rheumatoid arthritis has met its goals, the drug’s developers announced Wednesday.
British drug maker GlaxoSmithKline and Danish drug maker Genmab announced that patients in a phase 3 trial taking ofatumumab experienced a 20% improvement in the number of swollen and tender joints, as the companies expected.
In the 260-patient study, the 129 patients taking ofatumumab had a 50% response rate, compared to 27% of those taking placebo. The companies also said there were no unexpected safety problems, but 5% of patients experienced rash, hives, throat irritation and other side effects.
“We have always believed in ofatumumab’s potential to make a difference in patients’ lives,” Genmab CEO Lisa Drakeman said in a statement. “We are pleased with the results of this study, supporting the further investigation of this antibody’s promise in the treatment of RA.”
Medarex reports narrowed loss, nearly doubled revenue for Q2
PRINCETON, N.J. Biotech drug maker Medarex reported a less severe drop in second-quarter loss, while its revenue almost doubled from last year.
The Princeton, N.J.-based Medarex reported losses of $29.2 million compared with a loss of $53.1 million in the same quarter last year.
This year’s revenue was up 96% from last year’s $10 million to $19.5 million.
New York-based Bristol-Myers Squibb, the maker of blood thinner Plavix, put forth $2.1 billion to acquire Medarex.